文献类型：期刊文献

英文题名：Screening of an individualized treatment strategy for an advanced gallbladder cancer using patient-derived tumor xenograft and organoid models

作者：Tan, Dengxu[1,2];An, Jiaze[3];Gong, Miaomiao[4];Wang, Huihui[2];Li, Han[5];Meng, Han[1];Zhang, Caiqin[1];Zhao, Yong[1];Ge, Xu[1];Shi, Changhong[1]

第一作者：Tan, Dengxu

通信作者：Ge, X[1];Shi, CH[1]

机构：[1]Fourth Mil Med Univ, Lab Anim Ctr, Div Canc Biol, Xian, Shaanxi, Peoples R China;[2]Gansu Univ Chinese Med, Gansu Prov Lab Anim Ind Technol Ctr, Lanzhou, Gansu, Peoples R China;[3]Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary & Pancreaticosplen Surg, Xian, Peoples R China;[4]Med Coll Yanan Univ, Sch Basic Med Sci, Yanan, Peoples R China;[5]AF Mil Med Univ, Sch Basic Med, Grp 4, Xian, Shaanxi, Peoples R China

第一机构：Fourth Mil Med Univ, Lab Anim Ctr, Div Canc Biol, Xian, Shaanxi, Peoples R China

通信机构：[1]corresponding author), Fourth Mil Med Univ, Lab Anim Ctr, Div Canc Biol, Xian, Shaanxi, Peoples R China.

年份：2022

卷号：12

外文期刊名：FRONTIERS IN ONCOLOGY

收录：;Scopus(收录号：2-s2.0-85145044305);WOS:【SCI-EXPANDED(收录号:WOS:000903825600001)】；

语种：英文

外文关键词：gallbladder cancer; patient-derived tumor xenograft model; patient-derived tumor organoid model; individualized therapy; immune checkpoint inhibitors

摘要：Gallbladder cancer is a highly aggressive malignancy with poor sensitivity to postoperative radiotherapy or chemotherapy; therefore, the development of individualized treatment strategies is paramount to improve patient outcomes. Both patient-derived tumor xenograft (PDX) and patient-derived tumor organoid (PDO) models derived from surgical specimens can better preserve the biological characteristics and heterogeneity of individual original tumors, display a unique advantage for individualized therapy and predicting clinical outcomes. In this study, PDX and PDO models of advanced gallbladder cancer were established, and the consistency of biological characteristics between them and primary patient samples was confirmed using pathological analysis and RNA-sequencing. Additionally, we tested the efficacy of chemotherapeutic drugs, targeted drugs, and immune checkpoint inhibitors using these two models. The results demonstrated that gemcitabine combined with cisplatin induced significant therapeutic effects. Furthermore, treatment with immune checkpoint inhibitors elicited promising responses in both the humanized mice and PDO immune models. Based on these results, gemcitabine combined with cisplatin was used for basic treatment, and immune checkpoint inhibitors were applied as a complementary intervention for gallbladder cancer. The patient responded well to treatment and exhibited a clearance of tumor foci. Our findings indicate that the combined use of PDO and PDX models can guide the clinical treatment course for gallbladder cancer patients to achieve individualized and effective treatment.